Is VMSXF or JNJ a better dividend investment in 2026?

VMSXF currently yields 4597.70% with a 5% 5-year dividend growth rate. JNJ yields 2.13% with 5.8% growth. The better choice depends on your goal: VMSXF offers higher current income.

What is the dividend yield difference between VMSXF and JNJ?

VMSXF has a forward dividend yield of 4597.70% ($2.00/share annually). JNJ yields 2.13% ($5.20/share annually). The yield gap is 4595.57 percentage points.

Home › Compare › VMSXF vs JNJ

VMSXF vs JNJ: Dividend Comparison 2026

VMSXF yields 4597.70% · JNJ yields 2.13%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 VMSXF wins by $27574325089884.56M in total portfolio value

INVESTMENT

TIME HORIZON10 years

VMSXF

● Live price

4597.70%

Share price

$0.04

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$27574325089884.59M

Annual income

$26,442,949,176,723,448,000.00

Full VMSXF calculator →

JNJ

Johnson & Johnson

● Live price

2.13%

Share price

$244.44

Annual div

$5.20

5Y div CAGR

28%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.3K

Annual income

$4,689.40

Full JNJ calculator →

Portfolio growth — VMSXF vs JNJ

📍 VMSXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	VMSXF	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, VMSXF + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

VMSXF pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VMSXF

Annual income on $10K today (after 15% tax)

$390,804.60/yr

After 10yr DRIP, annual income (after tax)

$22,476,506,800,214,930,000.00/yr

JNJ

Annual income on $10K today (after 15% tax)

$180.82/yr

After 10yr DRIP, annual income (after tax)

$3,985.99/yr

At 15% tax rate, VMSXF beats the other by $22,476,506,800,214,925,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VMSXF + JNJ for your $10,000?

VMSXF: 50%JNJ: 50%

100% JNJ50/50100% VMSXF

Portfolio after 10yr

$13787162544942.31M

Annual income

$13,221,474,588,361,726,000.00/yr

Blended yield

95.90%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

VMSXF

No analyst data

Altman Z

4.9

Piotroski

1/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

-6.4% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VMSXF buys

JNJ buys

No recent congressional trades found for VMSXF or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricVMSXFJNJ

Forward yield	4597.70% ✓	2.13%
Annual dividend / share	$2.00	$5.20 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	28% ✓
Portfolio after 10y	$27574325089884.59M ✓	$30.3K
Annual income after 10y	$26,442,949,176,723,448,000.00 ✓	$4,689.40
Total dividends collected	$27497557748897.73M ✓	$15.4K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: VMSXF vs JNJ ($10,000, DRIP)

Year	VMSXF Portfolio	VMSXF Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$470,470	$459,770.11	$10,592	$272.30	+$459.9K → VMSXF
2	$20,719,113	$20,215,710.17	$11,289	$357.73	+$20.71M → VMSXF
3	$854,209,721	$832,040,270.28	$12,123	$472.89	+$854.20M → VMSXF
4	$32,973,295,528	$32,059,291,126.36	$13,141	$629.86	+$32973.28M → VMSXF
5	$1,191,840,933,523	$1,156,559,507,307.32	$14,408	$846.81	+$1191840.92M → VMSXF
6	$40,344,976,177,926	$39,069,706,379,057.06	$16,021	$1,151.60	+$40344976.16M → VMSXF
7	$1,279,194,924,336,751	$1,236,025,799,826,370.20	$18,122	$1,588.22	+$1279194924.32M → VMSXF
8	$37,994,867,716,203,110	$36,626,129,147,162,790.00	$20,930	$2,228.20	+$37994867716.18M → VMSXF
9	$1,057,360,666,505,737,600	$1,016,706,158,049,400,300.00	$24,792	$3,191.91	+$1057360666505.71M → VMSXF
10	$27,574,325,089,884,590,000	$26,442,949,176,723,448,000.00	$30,274	$4,689.40	+$27574325089884.56M → VMSXF

VMSXF vs JNJ: Complete Analysis 2026

VMSXF — Stock

Nine Mile Metals Ltd. engages in the acquisition, development, and exploration of mineral properties. It holds interests in Black Point Property located in Eureka County, Nevada. The company also holds interest in the Nine Mile Brook and the Canoe Landing Lake West mining projects located in New Brunswick, Canada. The company was formerly known as Stevens Gold Nevada Inc. and changed its name to Nine Mile Metals Ltd. in January 2022. Nine Mile Metals Ltd. was incorporated in 2018 and is headquartered in Vancouver, Canada.

Full VMSXF Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

📬

Get this VMSXF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VMSXF vs SCHD VMSXF vs JEPI VMSXF vs O VMSXF vs KO VMSXF vs MAIN VMSXF vs ABBV VMSXF vs MRK VMSXF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.